Solventum’s (SOLV) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Solventum (NYSE:SOLV) in a research report released on Friday,Benzinga reports. BTIG Research currently has a $100.00 price target on the stock.

SOLV has been the topic of a number of other reports. Mizuho set a $100.00 target price on shares of Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. KeyCorp raised shares of Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 price objective on the stock in a research report on Monday, January 26th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Stifel Nicolaus upped their target price on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Finally, Piper Sandler reissued an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $91.64.

Solventum Trading Down 3.7%

Shares of Solventum stock opened at $74.12 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The company has a fifty day simple moving average of $78.58 and a 200-day simple moving average of $76.25. The stock has a market cap of $12.86 billion, a price-to-earnings ratio of 8.36, a PEG ratio of 6.75 and a beta of 0.40. Solventum has a 12-month low of $60.70 and a 12-month high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The business’s revenue was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, equities analysts forecast that Solventum will post 6.58 EPS for the current fiscal year.

Solventum announced that its Board of Directors has approved a share buyback plan on Thursday, November 20th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to reacquire up to 7.5% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SOLV. Hilltop National Bank grew its position in Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after buying an additional 129 shares during the period. CrossGen Wealth LLC acquired a new stake in shares of Solventum in the 4th quarter worth approximately $25,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum in the 3rd quarter worth approximately $25,000. JNBA Financial Advisors increased its stake in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new position in Solventum during the second quarter worth $28,000.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q4 beat — SOLV reported $1.57 EPS and $2.0B revenue, topping estimates with strong demand in surgical/wound-care products, supporting the case for continued organic growth. Read More.
• Positive Sentiment: FY2026 guidance nudged above consensus — management set EPS guidance of $6.40–$6.60, slightly ahead of Street expectations, giving some visibility to full‑year earnings. Read More.
• Positive Sentiment: Analyst bullish signals — KeyCorp raised its price target to $99 (overweight) and BTIG reaffirmed a buy with a $100 target, reflecting upside from better-than-expected results and long-term growth potential. Read More. Read More.
• Neutral Sentiment: Full disclosure for investors — the earnings call transcript and slide deck are available for deeper review of segment performance and cost drivers. Read More.
• Negative Sentiment: Margin pressure — several reports and the company’s commentary highlighted declining margins and cost headwinds despite organic sales growth (organic sales +3.5%, overall sales -3.7% y/y), which is the primary driver of investor concern. Read More.
• Negative Sentiment: Analyst caution — Wells Fargo cut its price target to $83 and moved to an equal‑weight stance, signaling shorter-term skepticism that likely amplified selling after the print. Read More.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.